The Covid-19 pandemic has had a major effect on all of our lives. For many, the pandemic and ensuing social distancing measures have increased feelings of loneliness, stress, worry and other strong emotions putting mental health in the spotlight. As a result, many business and community leaders are placing a greater emphasis on emotional health and well-being.
In the six-plus years I’ve been at Alexion, I’ve seen many changes. One constant, though, has been our commitment to solutions informed by not only patients’ physical conditions, but also their social and emotional needs.
From my childhood in Pakistan, to my immigration to the United States, to my time living and working in Italy and throughout my entire career, my life has always put me in highly global contexts. These cross-cultural experiences have emboldened my relentless passion for human rights and etched the values of authenticity and inclusion into my personal credo.
There is no doubt that 2020 was a year of change – it changed the way we live, the way we work and the way we serve our communities. Yet, with all of the change, I was reminded of an important truth – we are all human, and together we are resilient.
Alexion is honored to receive the 2020 Corporate Partner of the Year Award from volunteer agency Boston Cares as part of their annual Boston Cares Awards recognizing outstanding volunteers and partners.
Alexion, a global biopharmaceutical company (NASDAQ: ALXN), is committed to all the communities we engage with including patients, caregivers and their families; our valued employees and future talent; our neighbors around the world; investors; patient organizations; suppliers; business partners and others. This collective passion comes to life in our 2020 Corporate Social Responsibility (CSR) report, Dear Communities, which is written from the first-person perspective of Alexion employees.
Alexion CEO Ludwig Hantson embodies the personal tone in his opening words:
The Alexion Charitable Foundation (ACF), launched by Alexion Pharmaceuticals, Inc. in February 2020, marks its first anniversary this month in tandem with the celebration of Rare Disease Day. The Foundation was established with the mission to offer promise and cultivate a sense of belonging, particularly for people affected by a rare disease. This article marks the major milestones made toward that purpose in year one and highlights the work of several unique grantees funded by the Foundation.
At Alexion, Corporate Social Responsibility (CSR) is an inherent part of everything we do and supports our mission to transform the lives of people affected by rare diseases and devastating conditions. In addition to developing and delivering life-changing medicines, this mission drives us to seek opportunities to advance innovative solutions to system-wide challenges faced by rare disease patients, such as the “diagnostic odyssey.”
Since 2018, Alexion has regularly engaged with a variety of external organizations to validate and evaluate our commitment to Corporate Social Responsibility (i.e., ESG). Sustainalytics, an organization that is one of the most widely respected evaluators of ESG (Environmental, Social and Governance) performance, just released their latest assessment of Alexion, and named us their #1 ranked biotech company for lowest ESG risk. Alexion is rated against all biotech companies in the Sustainalytics “universe” – a total of 373 companies.
October is Security Awareness Month and to celebrate, Alexion’s Global Security Team gave employees a “Backstage Pass” to learning how continuous vigilance keeps patients, our people and our assets safe.